Anzeige
Meldung des Tages: GBC Research sieht 200%-Chance: Millionen Gaslecks in den USA, Auftragsbuch wächst

Invesco Water Resources ETF Registered Shares News

ETF
WKN:  A2JNQQ ISIN:  US46137V1420 US-Symbol:  PHO
64,416 €
-0,15 $
-0,21%
64,416 € 21:46:00 Uhr
Depot/Watchlist
Indexbildung
Ertragsverwendung
-
Lfd. Kosten
-
Fondsgröße
-  
Tracking Error
-
Währung
FWW Fundstars
keine Bewertung

Invesco Water Resources ETF Registered Shares News

16.03.26 - PR Newswire
Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway
Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway PR Newswire
03.03.26 - PR Newswire
Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions
Asieris: CEVIRA Approved in China as First-​in-Class Non-​Invasive Therapy for Cervical Precancerous Lesions PR Newswire
03.03.26 - PR Newswire
Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions
Asieris: CEVIRA Approved in China as First-​in-Class Non-​Invasive Therapy for Cervical Precancerous Lesions PR Newswire
27.02.26 - PR Newswire
Photocure partner Asieris announces that EMA has accepted Marketing Authorization Application for CEVIRA in Europe
Photocure partner Asieris announces that EMA has accepted Marketing Authorization Application for CEVIRA in Europe PR Newswire
18.02.26 - PR Newswire
Photocure ASA: Results for the fourth quarter of 2025
Photocure ASA: Results for the fourth quarter of 2025 PR Newswire
18.02.26 - PR Newswire
Photocure ASA: Results for the fourth quarter of 2025
Photocure ASA: Results for the fourth quarter of 2025 PR Newswire
08.12.25 - PR Newswire
The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison
The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison PR Newswire
08.12.25 - PR Newswire
The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison
The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison PR Newswire
19.11.25 - PR Newswire
New budget impact model study in 4 European countries concludes that BLC use offers a clinically meaningful and economically rational approach to NMIBC management
New budget impact model study in 4 European countries concludes that BLC use offers a clinically meaningful and economically rational approach to NMIBC management PR ...
29.10.25 - PR Newswire
Photocure ASA: Results for the third quarter of 2025
Photocure ASA: Results for the third quarter of 2025 PR Newswire
29.10.25 - PR Newswire
Photocure ASA: Results for the third quarter of 2025
Photocure ASA: Results for the third quarter of 2025 PR Newswire

Newssuche

Videos

newspaper
22.10.26 0,00%
Technical Trading Ripple Crash voraus?!
Ripple Short Typ: Turbo Open End WKN: BD7NA4 Hebel: 1,99 Laufzeit: OpenEnd Einstieg: Market ... Mehr »
Weitere Videos ❯

Weitere Vorteile:

  • Kursalarme
  • Watchlists & Musterdepots
  • Börsenspiele & Community-Forum
  • Historische Kurse im CSV-Format
  • News & Themen abonnieren

Neuer Vorteil im Pur-Abo

Mit dem Pur-Abo laufen deine Abfragen jetzt ungebremst:

✓ Bis zu 5.000 Abfragen pro Stunde
✓ Keine IP-Sperren mehr bei Excel-Makros und Skripten
✓ IP-Adresse selbst freischalten, in wenigen Sekunden erledigt
Jetzt Pur-Abo abschließen →

Schon Pur-Abonnent? IP hier freischalten